HUYABIO International has announced regulatory approval of Hiyasta® (HBI-8000) monotherapy by the Ministry of Health, Labour and Welfare (MHLW) of Japan for the treatment of relapsed or refractory (R/R) Peripheral T-cell lymphoma (PTCL). This approval is based on results of a study of 55 patients with aggressive cases of PTCL in both Japan and Korea, all with refractory or relapsed cases despite prior therapies. Traditionally, a R/R PTCL diagnosis is associated with a poor long-term prognosis with very few treatment options. HBI-8000, which aims to address this unmet medical need among patient populations with advanced cases of PTCL, acts as an epigenetic immunomodulator which uses specific targeting of malignant cells to cause arrest of the cell cycle and subsequent cell death. As an industry leader in accelerating global development of therapeutic innovations in China, HUYABIO International is focused on improving speed, cost-effectiveness, and reducing risk of drug development by relying on biopharmaceutical, academic, and commercial collaboration.
Read more here.